Abatacept monotherapy compared with abatacept plus disease-modifying anti-rheumatic drugs in rheumatoid arthritis patients: data from the ORA registry
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1478-6362
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Abatacept monotherapy compared with abatacept plus disease-modifying anti-rheumatic drugs in rheumatoid arthritis patients: data from the ORA registry ; volume:18 ; number:1 ; day:30 ; month:3 ; year:2016 ; pages:1-8 ; date:12.2016
Arthritis Research & Therapy ; 18, Heft 1 (30.3.2016), 1-8, 12.2016
- Urheber
-
Truchetet, Marie-Elise
- Beteiligte Personen und Organisationen
-
Poursac, Nicolas
Barnetche, Thomas
Shipley, Emilie
Gottenberg, Jacques-Eric
Bannwarth, Bernard
Richez, Christophe
Schaeverbeke, Thierry
SpringerLink (Online service)
- DOI
-
10.1186/s13075-016-0956-7
- URN
-
urn:nbn:de:1111-20160401309
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:44 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Truchetet, Marie-Elise
- Poursac, Nicolas
- Barnetche, Thomas
- Shipley, Emilie
- Gottenberg, Jacques-Eric
- Bannwarth, Bernard
- Richez, Christophe
- Schaeverbeke, Thierry
- SpringerLink (Online service)
Ähnliche Objekte (12)
The sequence of disease-modifying anti-rheumatic drugs: pathways to and predictors of tocilizumab monotherapy
Abatacept vermindert Rezidivrisiko bei Riesenzellarteriitis
Abatacept : zehn Jahre Abatacept: Rationale für den Einsatz bei der frühen schnell fortschreitenden RA
Abatacept used in combination with non-methotrexate disease-modifying antirheumatic drugs: a descriptive analysis of data from interventional trials and the real-world setting
Abatacept used in combination with non-methotrexate disease-modifying antirheumatic drugs: a descriptive analysis of data from interventional trials and the real-world setting
Abatacept used in combination with non-methotrexate disease-modifying antirheumatic drugs : : a descriptive analysis of data from interventional trials and the real-world setting
Abatacept used in combination with non-methotrexate disease-modifying antirheumatic drugs : a descriptive analysis of data from interventional trials and the real-world setting
Safety of abatacept compared with other biologic and conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: data from an observational study
Utilizing biologic disease-modifying anti-rheumatic treatment sequences to subphenotype rheumatoid arthritis
Abatacept wirkt nachhaltig bei jedem Lebensalter
Takayasu-Arteriitis. Abatacept ohne nachweisbaren Nutzen
Infektionsrisiken durch Abatacept, Rituximab oder Tocilizumab analysiert
The sequence of disease-modifying anti-rheumatic drugs: pathways to and predictors of tocilizumab monotherapy
Abatacept vermindert Rezidivrisiko bei Riesenzellarteriitis
Abatacept : zehn Jahre Abatacept: Rationale für den Einsatz bei der frühen schnell fortschreitenden RA
Abatacept used in combination with non-methotrexate disease-modifying antirheumatic drugs: a descriptive analysis of data from interventional trials and the real-world setting
Abatacept used in combination with non-methotrexate disease-modifying antirheumatic drugs: a descriptive analysis of data from interventional trials and the real-world setting
Abatacept used in combination with non-methotrexate disease-modifying antirheumatic drugs : : a descriptive analysis of data from interventional trials and the real-world setting
Abatacept used in combination with non-methotrexate disease-modifying antirheumatic drugs : a descriptive analysis of data from interventional trials and the real-world setting
Safety of abatacept compared with other biologic and conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: data from an observational study
Utilizing biologic disease-modifying anti-rheumatic treatment sequences to subphenotype rheumatoid arthritis
Abatacept wirkt nachhaltig bei jedem Lebensalter
Takayasu-Arteriitis. Abatacept ohne nachweisbaren Nutzen
Infektionsrisiken durch Abatacept, Rituximab oder Tocilizumab analysiert
The sequence of disease-modifying anti-rheumatic drugs: pathways to and predictors of tocilizumab monotherapy
Abatacept vermindert Rezidivrisiko bei Riesenzellarteriitis
Abatacept : zehn Jahre Abatacept: Rationale für den Einsatz bei der frühen schnell fortschreitenden RA
Abatacept used in combination with non-methotrexate disease-modifying antirheumatic drugs: a descriptive analysis of data from interventional trials and the real-world setting
Abatacept used in combination with non-methotrexate disease-modifying antirheumatic drugs: a descriptive analysis of data from interventional trials and the real-world setting
Abatacept used in combination with non-methotrexate disease-modifying antirheumatic drugs : : a descriptive analysis of data from interventional trials and the real-world setting
Abatacept used in combination with non-methotrexate disease-modifying antirheumatic drugs : a descriptive analysis of data from interventional trials and the real-world setting
Safety of abatacept compared with other biologic and conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: data from an observational study
Utilizing biologic disease-modifying anti-rheumatic treatment sequences to subphenotype rheumatoid arthritis
Abatacept wirkt nachhaltig bei jedem Lebensalter
Takayasu-Arteriitis. Abatacept ohne nachweisbaren Nutzen